These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 27610200)

  • 1. Adoptive cell therapy and modulation of the tumour microenvironment: new insights from ASCO 2016.
    Khoja L; Gyawali B
    Ecancermedicalscience; 2016; 10():ed59. PubMed ID: 27610200
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Landscape of Adoptive Cellular Therapies in Ovarian Cancer.
    Davis L; Miller RE; Wong YNS
    Cancers (Basel); 2023 Sep; 15(19):. PubMed ID: 37835509
    [TBL] [Abstract][Full Text] [Related]  

  • 3. From a Patient Advocate's Perspective: Does Cancer Immunotherapy Represent a Paradigm Shift?
    Madden DL
    Curr Oncol Rep; 2018 Feb; 20(1):8. PubMed ID: 29411148
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of Long-term Survival Benefits in Trials of Immune Checkpoint Inhibitor vs Non-Immune Checkpoint Inhibitor Anticancer Agents Using ASCO Value Framework and ESMO Magnitude of Clinical Benefit Scale.
    Everest L; Shah M; Chan KKW
    JAMA Netw Open; 2019 Jul; 2(7):e196803. PubMed ID: 31290990
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adoptive Cell Therapy-Harnessing Antigen-Specific T Cells to Target Solid Tumours.
    Chruściel E; Urban-Wójciuk Z; Arcimowicz Ł; Kurkowiak M; Kowalski J; Gliwiński M; Marjański T; Rzyman W; Biernat W; Dziadziuszko R; Montesano C; Bernardini R; Marek-Trzonkowska N
    Cancers (Basel); 2020 Mar; 12(3):. PubMed ID: 32183246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immuno-oncologic Approaches: CAR-T Cells and Checkpoint Inhibitors.
    Gay F; D'Agostino M; Giaccone L; Genuardi M; Festuccia M; Boccadoro M; Bruno B
    Clin Lymphoma Myeloma Leuk; 2017 Aug; 17(8):471-478. PubMed ID: 28689001
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current status of chimeric antigen receptor engineered T cell-based and immune checkpoint blockade-based cancer immunotherapies.
    Hegde UP; Mukherji B
    Cancer Immunol Immunother; 2017 Sep; 66(9):1113-1121. PubMed ID: 28497159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adoptive immunotherapy for cancer.
    Ruella M; Kalos M
    Immunol Rev; 2014 Jan; 257(1):14-38. PubMed ID: 24329787
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospects for personalized combination immunotherapy for solid tumors based on adoptive cell therapies and immune checkpoint blockade therapies.
    Kato D; Yaguchi T; Iwata T; Morii K; Nakagawa T; Nishimura R; Kawakami Y
    Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(1):68-77. PubMed ID: 28539557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune checkpoint targeting as anti-cancer immunotherapy: promises, questions, challenges and the need for predictive biomarkers at ASCO 2015.
    Pandha H; Pawelec G
    Cancer Immunol Immunother; 2015 Sep; 64(9):1071-4. PubMed ID: 26267043
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chimeric Antigen Receptors for the Tumour Microenvironment.
    Habib R; Nagrial A; Micklethwaite K; Gowrishankar K
    Adv Exp Med Biol; 2020; 1263():117-143. PubMed ID: 32588326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adoptive CD8
    Jiang X; Xu J; Liu M; Xing H; Wang Z; Huang L; Mellor AL; Wang W; Wu S
    Cancer Lett; 2019 Oct; 462():23-32. PubMed ID: 31356845
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Marrow-Infiltrating Lymphocytes - Role in Biology and Cancer Therapy.
    Borrello I; Noonan KA
    Front Immunol; 2016; 7():112. PubMed ID: 27066005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacologic Modulation of Human Immunity in the Era of Immuno-oncology: Something Old, Something New.
    Bangalore Kumar A; Maus R; Markovic SN
    Mayo Clin Proc; 2018 Jul; 93(7):917-936. PubMed ID: 29887221
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current Challenges in Cancer Treatment.
    Zugazagoitia J; Guedes C; Ponce S; Ferrer I; Molina-Pinelo S; Paz-Ares L
    Clin Ther; 2016 Jul; 38(7):1551-66. PubMed ID: 27158009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical cancer advances 2011: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology.
    Vogelzang NJ; Benowitz SI; Adams S; Aghajanian C; Chang SM; Dreyer ZE; Janne PA; Ko AH; Masters GA; Odenike O; Patel JD; Roth BJ; Samlowski WE; Seidman AD; Tap WD; Temel JS; Von Roenn JH; Kris MG
    J Clin Oncol; 2012 Jan; 30(1):88-109. PubMed ID: 22147736
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Immuno-, radio-, and chemotherapeutic studies in head and neck cancer : Highlights of the ASCO Annual Meeting 2017].
    Schuler PJ; von Witzleben A; Doescher J; Wollenberg B; Dietz A; Hoffmann TK
    HNO; 2018 Mar; 66(3):212-218. PubMed ID: 29460015
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Switching on the green light for chimeric antigen receptor T-cell therapy.
    Mardiana S; Lai J; House IG; Beavis PA; Darcy PK
    Clin Transl Immunology; 2019; 8(5):e1046. PubMed ID: 31073403
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Cancer Advances 2018: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology.
    Heymach J; Krilov L; Alberg A; Baxter N; Chang SM; Corcoran RB; Dale W; DeMichele A; Magid Diefenbach CS; Dreicer R; Epstein AS; Gillison ML; Graham DL; Jones J; Ko AH; Lopez AM; Maki RG; Rodriguez-Galindo C; Schilsky RL; Sznol M; Westin SN; Burstein H
    J Clin Oncol; 2018 Apr; 36(10):1020-1044. PubMed ID: 29380678
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single-cell technologies for profiling T cells to enable monitoring of immunotherapies.
    An X; Varadarajan N
    Curr Opin Chem Eng; 2018 Mar; 19():142-152. PubMed ID: 31131208
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.